Applied Proteomics announces the closing of its $28 million dollar Series C financing.
With this Series C financing investment, API will begin commercializing its novel diagnostic tools and move closer to achieving its vision of saving lives and reducing healthcare costs through precision medicine.
This round of series C financing was led by Genting Berhad, with existing investors Domain Associates and Vulcan Capital also participating in the financing.
Genting Berhad Chairman and CEO Tan Sri Lim Kok Thay was appointed to the API Board of Directors after the series C financing round.
Report: Colorectal Cancer Partnering
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity